Epstein-Barr virus encoded latent membrane protein (LMP1) and tnf receptor associated factors (TRaF): Colocalisation of LMP1 and TRAF1 in primary EBV infection and in EBV associated Hodgkin lymphoma

Journal of Clinical Pathology - Molecular Pathology

Volumn 56, Issue 3, 2003, Pages 156-161

  Siegler, G ^a   Kremmer, E ^b   Gonnella, R ^b   Niedobitek, G ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b INSTITUTE OF EPIDEMIOLOGY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

LATENT MEMBRANE PROTEIN 1; PROTEIN DERIVATIVE; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 1; UNCLASSIFIED DRUG;

ANAPLASTIC CARCINOMA; ARTICLE; B CELL LYMPHOMA; B LYMPHOCYTE; BURKITT LYMPHOMA; CONFOCAL LASER MICROSCOPY; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ASSOCIATION; EPSTEIN BARR VIRUS; FOLLICULAR LYMPHOMA; GENETIC CODE; HODGKIN DISEASE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOFLUORESCENCE; IN VIVO STUDY; INFECTIOUS MONONUCLEOSIS; LARGE CELL LYMPHOMA; LATENT PERIOD; LYMPHOCYTE; LYMPHOCYTE PROLIFERATION; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; RETICULOENDOTHELIAL SYSTEM; SIGNAL TRANSDUCTION; TONSIL; TUMOR BIOPSY; VIRUS CARCINOGENESIS; VIRUS CARRIER; VIRUS INFECTION;

EID: 0037633965     PISSN: 13668714     EISSN: None     Source Type: Journal    
DOI: 10.1136/mp.56.3.156     Document Type: Article

References (39)

1. International Agency for Research on Cancer. Epstein-Barr virus and Kaposi's sarcoma herpesvirus/human herpesvirus 8. Lyon, France: World Health Organisation, 1997.
2. Wang D, Liebowitz D, Kieff E. An EBV membrane protein expressed in immortalized lymphocytes transforms established rodent cells. Cell 1985;43:831-40.
3. Wang D, Leibowitz D, Wang F, et al. Epstein-Barr virus latent infection membrane protein alters the human B-lymphocyte phenotype: deletion of the amino terminus abolishes activity. J Virol 1988;62:4173-84.
4. Wang F, Gregory CD, Sample C, et al. Epstein-Barr virus latent membrane protein (LMP-1) and nuclear proteins 2 and 3C are effectors of phenotypic changes in B lymphocytes: EBNA2 and LMP-1 cooperatively induce CD23. J Virol 1990;64:2309-18.
5. Dawson CW, Rickinson AB, Young LS. Epstein-Barr virus latent membrane protein inhibits human epithelial cell differentiation. Nature 1990;344:777-80.
6. Peng M, Lundgren E. Transient expression of the Epstein-Barr virus LMP1 gene in human primary B cells induces cellular activation and DNA synthesis. Oncogene 1992;7:1775-82.
7. Rowe M, Peng-Pilon M, Huen DS, et al. Upregulation of bcl-2 by the Epstein-Barr virus latent membrane protein LMP1: a B-cell specific response that is delayed relative to NF-κb activation and to induction of cell surface markers. J Virol 1994;68:122-31.
8. Laherty CD, Hu HM, Opipari AW, et al. Epstein-Barr virus LMP1 gene product induces A20 zinc finger protein expression by activating nuclear factor κB. J Biol Chem 1992;267:24157-60.
9. Fries KL, Miller WE, Raab-Traub N. The A20 protein interacts with the Epstein-Barr virus latent membrane protein 1 (LMP1) and alters the LMP1/TRAF1/TRADD complex. Virology 1999;264:159-66.
10. Mosialos G, Birkenbach M, Yalamanchili R, et al. The Epstein-Barr virus transforming protein LMP1 engages signaling proteins for the tumour necrosis factor receptor family. Cell 1995;80:389-99.
11. Kilger E, Kieser A, Baumann M, et al. Epstein-Barr virus-mediated B-cell proliferation is dependent upon latent membrane protein 1, which simulates an activated CD40 receptor. EMBO J 1998;17:1700-9.
12. Eliopoulos AG, Stack M, Dawson CW, et al. Epstein-Barr virus-encoded LMP1 and CD40 mediate IL-6 production in epithelial cells via an NF-κB pathway involving TNF receptor-associated factors. Oncogene 1997;14:2899-916.
13. Floettmann JE, Eliopoulos AG, Jones M, et al. Epstein-Barr virus latent membrane protein-1 (LMP1) signalling is distinct from CD40 and involves physical cooperation of its two C-terminus functional regions. Oncogene 1998;17:2383-92.
14. Rowe M. The EBV latent membrane protein-1 (LMP1): a tale of two functions. Epstein-Barr Virus Report 1995;2:99-104.
15. Devergne O, Hatzivassiliou E, Izumi KM, et al. Association of TRAF1, TRAF2, and TRAF3 with an Epstein-Barr virus LMP1 domain important for B-lymphocyte transformation: role in NF-κB activation. Mol Cell Biol 1996;16:7098-7108.
16. Sylla BS, Hung SC, Davidson DM, et al. Epstein-Barr virus-transforming protein latent infection membrane protein 1 activates transcription factor NF-κB through a pathway that includes the NF-κB-inducing kinase and the IκB kinases IKKα and IKKβ. Proc Natl Acad Sci U S A 1998;95:10106-11.
17. Eliopoulos A, Young LS. Activation of the cJun N-terminal kinase (JNK) pathway by the Epstein-Barr virus-encoded latent membrane protein 1 (LMP1). Oncogene 1998;16:1731-42.
18. Kieser A, Kilger E, Gires O, et al. Epstein-Barr virus latent membrane protein-1 triggers AP-1 activity via the c-jun N-terminal kinase cascade. EMBO J 1997;16:6478-85.
19. Roberts ML, Cooper NR. Activation of a Ras-MAPK-dependent pathway by Epstein-Barr virus latent membrane protein 1 is essential for cellular transformation. Virology 1998;240:93-9.
20. Eliopoulos AG, Gallagher NJ, Blake SMS, et al. Activation of the p38 mitogen-activated protein kinase pathway by Epstein-Barr virus-encoded latent membrane protein 1 coregulates interleukin-6 and interleukin-8 production. J Biol Chem 1999;274:16085-96.
21. Devergne O, McFarland EC, Mosialos G, et al. Role of TRAF binding site and NF-κB activation in Epstein-Barr virus latent membrane protein 1-induced cell gene expression. J Virol 1998;72:7900-8.
22. Craxton A, Shu G, Graves JD, et al. p38 MAPK is required for CD40-induced gene expression and proliferation in B lymphocytes. J Immunol 1998;161:3225.
23. Liebowitz D. Epstein-Barr virus and cellular signaling pathway in lymphomas from immunosuppressed patients. N Engl J Med 1998;338:1413-21.
24. Dürkop H, Foss H-D, Demel G, et al. Tumor necrosis factor receptor-associated factor 1 is overexpressed in Reed-Sternberg cells of Hodgkin disease and Epstein-Barr virus transformed lymphoid cells. Blood 1999;93:617-23.
25. Messineo C, Jamerson MH, Hunter E, et al. Gene expression by single Reed-Sternberg cells: pathways of apoptosis and activation. Blood 1998;91:2443-51.
26. Izban KF, Ergin M, Martinez RL, et al. Expression of the tumor necrosis factor receptor-associated factors (TRAFs) 1 and 2 is a characteristic feature of Hodgkin and Reed-Sternberg cells. Mod Pathol 2000;13:1324-31.
27. Murray PG, Flavell JR, Baumforth KRN, et al. Expression of the tumour necrosis factor receptor-associated factors 1 and 2 in Hodgkin disease. J Pathol 2001;194:158-64.
28. Beck A, Päzolt D, Grabenbauer GG, et al. Expression of cytokine and chemokine genes in Epstein-Barr virus-associated nasopharyngeal carcinoma and Hodgkin disease. J Pathol 2001;194:145-51.
29. Niedobitek G, Agathanggelou A, Rowe M, et al. Heterogeneous expression of Epstein-Barr virus latent proteins in endemic Burkitt lymphoma. Blood 1995;86:659-65.
30. Niedobitek G, Herbst H. In situ detection of Epstein-Barr virus DNA and of viral gene products. In: Wilson JB, May GHW, eds. Epstein-Barr virus protocols. Totowa, NJ: Humana Press, 2001:79-91.
31. Herbst H, Niedobitek G. Phenotype determination of Epstein-Barr virus infected cells in tissue sections. In: Wilson JB, May GHW, eds. Epstein-Barr virus protocols. Totowa, NJ: Humana Press, 2001:93-102.
32. Zapata JM, Krajewska M, Krajewski S, et al. TNFR-associated factor family protein expression in normal tissues and lymphoid malignancies. J Immunol 2000;165:5084-96.
33. Niedobitek G, Agathanggelou A, Herbst H, et al. Epstein-Barr virus (EBV) infection in infectious mononucleosis: virus latency, replication and phenotype of EBV-infected cells. J Pathol 1997;182:151-9.
34. Henriquez NV, Floettmann E, Salmon M, et al. Differential response to CD40 ligation among Burkitt lymphoma lines that are uniformly responsive to Epstein-Barr virus latent membrane protein. J Immunol 1999;162:3298-307.
35. Zapata JM, Reed JC. TRAF1: lord without a RING. Science's STKE 2002;2002 (133):PE27.
36. Thorley-Lawson DA, Babcock GJ. A model for persistent infection with Epstein-Barr virus: the stealth virus of human B cells. Life Sci 1999;14:1433-53.
37. Hinz M, Löser P, Mathas S, et al. Constitutive NF-κB maintains high expression of a characteristic gene network, including CD40, CD86, and a set of antiapoptotic genes in Hodgkin/Reed-Sternberg cells. Blood 2001;97:2798-807.
38. Carbone A, Gloghini A, Gattei V, et al. Expression of functional CD40 antigen on Reed-Sternberg cells and Hodgkin disease cell lines. Blood 1995;85:780-9.
39. Bargou RC, Emmerich F, Krappmann D, et al. Constitutive nuclear factor-κB-RelA activation is required for proliferation and survival of Hodgkin disease tumor cells. J Clin Invest 1997;100:2961-9.